Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043148 | 1.00 | METTL3 (0.43) | METTL3HCRTR1HCRTR2MAPK1KDM1A | |
| SCHEMBL4739206 | 0.97 | MAPK1 (0.43) | METTL3HCRTR1HCRTR2MAPK1OPRD1 | |
| SCHEMBL4739213 | 0.97 | MAPK1 (0.43) | METTL3HCRTR1HCRTR2MAPK1OPRD1 | |
| SCHEMBL1398781 | 0.94 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL1398784 | 0.83 | HCRTR1 (0.55) | METTL3HCRTR1HCRTR2MAPK1OPRD1 | |
| SCHEMBL923725 | 0.81 | HCRTR1 (0.50) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL2447646 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL496234 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL1571300 | 0.80 | HCRTR1 (0.58) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL3415424 | 0.79 | HCRTR1 (0.54) | HCRTR1HCRTR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-2155739-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008087611-A2 | PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | METTL3 4033/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.